After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Iovance Biotherapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $14.93 and fluctuated between $15.01 as its day high and $13.70 as its day low. The current market capitalization of Iovance Biotherapeutics Inc is $4.17B. A total of 5.86 million shares were traded on the day, compared to an average of 10.74M shares.
In the most recent transaction, Rothbaum Wayne P. bought 5,000,000 shares of IOVA for 9.15 per share on Feb 20 ’24. After the transaction, the Director now owns 28,067,333 company shares. In a previous transaction on Feb 20 ’24, MCPEAK MERRILL A bought 250,000 shares at 9.15 per share. IOVA shares that Director owns now total 320,150.
Among the insiders who bought shares, Dukes Iain D. acquired of 32,000 shares on Feb 20 ’24 at a per-share price of $9.15. This resulted in the Director holding 54,000 shares of IOVA after the transaction. In another insider transaction, MCPEAK MERRILL A bought 10,000 shares at $5.56 per share on Sep 18 ’23. Company shares held by the Director now total 248,633.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, IOVA has a high of $18.33 and a low of $3.21.
As of this writing, IOVA has an earnings estimate of -$0.42 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.32 per share and a lower estimate of -$0.5. The company reported an EPS of -$0.46 in the last quarter, which was -2.20% lower than expectations of -$0.45.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. IOVA’s latest balance sheet shows that the firm has $504.41M in Cash & Short Term Investments as of fiscal 2021. There were $71.53M in debt and $89.20M in liabilities at the time. Its Book Value Per Share was $2.28, while its Total Shareholder’s Equity was $621.66M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IOVA is Buy with a score of 4.86.
